Stock Price Forecast

March 4, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Zogenix Inc chart...

About the Company

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

CEO

Stephen Farr

Exchange

NASDAQ

Website

www.zogenix.com

$82M

Total Revenue

218

Employees

$1B

Market Capitalization

-6.56

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ZGNX News

Did Hedge Funds Make The Right Call On Zogenix, Inc. (ZGNX)

1y ago, source: AOL

With this in mind, let’s take a look at the recent hedge fund activity surrounding Zogenix, Inc. (NASDAQ:ZGNX) and determine whether hedge funds had an edge regarding this stock. Video ...

After epilepsy setback, Zogenix buys Modis and rare disease drug for $400m

4y ago, source: pharmaphorum

Zogenix will also pay a 5% royalty on any future net sales of MT1621. Zogenix’s other drug candidate for a rare kind of childhood epilepsy is facing a delay after the FDA refused in April to ...

Domain Partners VI, L.P.'s Net Worth

1mon ago, source: Benzinga.com

Who is Domain Partners VI, L.P.? Domain Partners VI, L.P. has an estimated net worth of $86.7 Million. This is based on reported shares across multiple companies, which include ZOGENIX, INC ...

Kim P. Kamdar's Net Worth

23d ago, source: Benzinga.com

Who is Kim P. Kamdar? Kim P. Kamdar has an estimated net worth of $2.25 Million. This is based on reported shares across multiple companies, which include MARINUS PHARMACEUTICALS INC, GLAUKOS Corp ...

Sweet Baby Inc. Doesn’t Do What Some Gamers Think It Does

23d ago, source: Kotaku

Sweet Baby Inc. is not the largest narrative design company in the games industry. Nor is it solely responsible for the characters and stories in recent high-profile releases like Alan Wake 2 ...

Welcome to Inc.'s Directory of B2B Excellence

5mon ago, source: Inc

They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.

STIHL Inc.

7mon ago, source: Forbes

This company has paid to receive expanded profile features. About STIHL Inc. Virginia-based STIHL Inc. is the U.S. affiliate for the global STIHL group and the manufacturer of the number one ...

Snap Inc Class A

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

About Inc.com | Everything You Need to Know to Grow and Start Your Business

12y ago, source: Inc

Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...

Apple Inc.

11mon ago, source: Wall Street Journal

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

P10, Inc. (PX) Stock Price, News, Quote & History - Yahoo Finance

15d ago, source: Yahoo Finance

P10 ( NYSE:PX ) Full Year 2023 Results Key Financial Results Revenue: US$241.7m (up 22% from FY 2022). Net loss... P10, Inc. (NYSE:PX) Q4 2023 Earnings Call Transcript February 29, 2024 P10, Inc ...

Snap Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...